Uxin Reports Non-GAAP EPS of $0.00 and Revenue of $123.51M; Provides Q4 Guidance and Updates Full-Year Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy UXIN?
Source: SeekingAlpha
Q3 Financial Performance: Uxin reported a non-GAAP EPS of $0.00 and revenue of $123.51 million, reflecting a 76.8% year-over-year increase. The adjusted EBITDA showed a loss of RMB5.3 million (US$0.7 million) for the quarter ending September 30, 2025.
Transaction Volume Growth: The company achieved a transaction volume of 15,904 units for Q3 2025, marking a 37.0% increase from the previous quarter and a 125.7% increase from the same period last year. Retail transaction volume also rose significantly to 14,020 units.
Future Outlook: Uxin anticipates retail transaction volume to be between 18,500 and 19,000 units for Q4 2025, with total revenues projected to range from RMB1,150 million to RMB1,180 million. For the full year, retail transaction volume is expected to exceed 50,000 units.
Strategic Partnerships: Uxin has partnered with Yinchuan authorities to establish a used car superstore, indicating a strategic move to enhance its market presence and sales capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UXIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UXIN
About UXIN
Uxin Ltd is a company mainly engaged in operating used car e-commerce platform in China. The Company is engaged in the provision of a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection and reconditioning, warehousing, as well as pre-sales and after-sales services. The vehicle sales business consists of retail vehicle sales business and wholesale vehicle sales business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
Uxin Secures $50 Million Funding to Accelerate Expansion
- Funding Support: Uxin has entered into binding agreements with NIO Capital and Prestige Shine Group to secure $50 million in funding, which strengthens the company's financial foundation and supports its nationwide superstore expansion.
- Performance Growth: For the quarter ending September 30, 2025, Uxin reported total revenue of 879.3 million Chinese yuan (approximately $123.5 million), marking significant year-over-year growth, with retail vehicle sales exceeding 14,000 units, more than doubling from the previous year, indicating strong market demand.
- Profitability Improvement: Uxin's gross margin increased to 7.5%, while operating and adjusted EBITDA losses narrowed, demonstrating the company's ability to enhance profitability despite rising expansion and marketing costs through higher sales volumes and improved unit economics.
- Future Plans: Founder and CEO Kun Dai stated that the new capital will fund the opening of 4 to 6 new superstores in 2026, further enhancing the company's market competitiveness and financial stability.
See More
Uxin Limited Secures $50 Million Financing from NIO Capital and Prestige Shine Group
- Significant Financing: Uxin Limited has entered into share subscription agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares at $0.00953 each, totaling $50 million, reflecting strong investor confidence in Uxin's future growth.
- Clear Use of Proceeds: The financing is expected to provide sufficient capital to support the launch of four to six new superstores in 2026, which will not only enhance the company's market expansion capabilities but also strengthen its overall financial resilience.
- Strong Investor Background: NIO Capital is committing $20 million while Prestige Shine Group is investing $30 million, indicating Uxin's attractiveness in the industry and its potential for growth.
- Strategic Development Focus: Uxin's Founder and CEO Kun Dai stated that the financing will support the company's long-term strategic goals, aiming to increase market share and brand influence through the establishment of new stores.
See More
Uxin Secures $50 Million Financing Agreement with NIO Capital and Prestige Shine Group
- Financing Scale: Uxin has entered into agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares, raising a total of $50 million, which reflects strong investor confidence in the company's strategic direction.
- Investment Allocation: NIO Capital will invest $20 million while Prestige Shine Group will contribute $30 million, with proceeds earmarked for launching 4 to 6 new superstores in 2026, thereby enhancing the company's competitive position in the market.
- Financial Resilience: This financing is expected to not only strengthen Uxin's balance sheet but also enhance overall financial resilience, providing sufficient capital support for future expansion plans.
- Market Strategy: Uxin aims to continue executing its established strategy by leveraging new retail experiences and digital empowerment to steadily expand operations in China's used car market, committed to delivering long-term value for shareholders.
See More
Uxin Secures $50 Million Financing from NIO Capital and Prestige Shine Group
- Significant Financing: Uxin has entered into agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares, raising a total of $50 million, which underscores strong investor confidence in the company's strategic direction.
- Clear Investment Allocation: NIO Capital is investing $20 million while Prestige Shine Group is contributing $30 million, with proceeds earmarked for launching four to six new superstores in 2026, thereby enhancing competitive positioning.
- Financial Resilience Boost: This financing is expected to strengthen Uxin's balance sheet and enhance overall financial resilience, enabling the company to continue its expansion in China's used car retail market.
- Ongoing Strategic Execution: Uxin will persist in executing its established strategy, leveraging new retail experiences and digital empowerment to drive industry transformation and improve customer satisfaction, ultimately delivering long-term value for shareholders.
See More
Uxin (UXIN) Q4 2025 Earnings Call Transcript
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
Uxin Secures $50 Million Funding to Accelerate Expansion
- Funding Support: Uxin has entered into binding agreements with NIO Capital and Prestige Shine Group to secure $50 million in funding, which strengthens the company's financial foundation and supports its nationwide superstore expansion.
- Performance Growth: For the quarter ending September 30, 2025, Uxin reported total revenue of 879.3 million Chinese yuan (approximately $123.5 million), marking significant year-over-year growth, with retail vehicle sales exceeding 14,000 units, more than doubling from the previous year, indicating strong market demand.
- Profitability Improvement: Uxin's gross margin increased to 7.5%, while operating and adjusted EBITDA losses narrowed, demonstrating the company's ability to enhance profitability despite rising expansion and marketing costs through higher sales volumes and improved unit economics.
- Future Plans: Founder and CEO Kun Dai stated that the new capital will fund the opening of 4 to 6 new superstores in 2026, further enhancing the company's market competitiveness and financial stability.
See More
Uxin Limited Secures $50 Million Financing from NIO Capital and Prestige Shine Group
- Significant Financing: Uxin Limited has entered into share subscription agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares at $0.00953 each, totaling $50 million, reflecting strong investor confidence in Uxin's future growth.
- Clear Use of Proceeds: The financing is expected to provide sufficient capital to support the launch of four to six new superstores in 2026, which will not only enhance the company's market expansion capabilities but also strengthen its overall financial resilience.
- Strong Investor Background: NIO Capital is committing $20 million while Prestige Shine Group is investing $30 million, indicating Uxin's attractiveness in the industry and its potential for growth.
- Strategic Development Focus: Uxin's Founder and CEO Kun Dai stated that the financing will support the company's long-term strategic goals, aiming to increase market share and brand influence through the establishment of new stores.
See More
Uxin Secures $50 Million Financing Agreement with NIO Capital and Prestige Shine Group
- Financing Scale: Uxin has entered into agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares, raising a total of $50 million, which reflects strong investor confidence in the company's strategic direction.
- Investment Allocation: NIO Capital will invest $20 million while Prestige Shine Group will contribute $30 million, with proceeds earmarked for launching 4 to 6 new superstores in 2026, thereby enhancing the company's competitive position in the market.
- Financial Resilience: This financing is expected to not only strengthen Uxin's balance sheet but also enhance overall financial resilience, providing sufficient capital support for future expansion plans.
- Market Strategy: Uxin aims to continue executing its established strategy by leveraging new retail experiences and digital empowerment to steadily expand operations in China's used car market, committed to delivering long-term value for shareholders.
See More
Uxin Secures $50 Million Financing from NIO Capital and Prestige Shine Group
- Significant Financing: Uxin has entered into agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares, raising a total of $50 million, which underscores strong investor confidence in the company's strategic direction.
- Clear Investment Allocation: NIO Capital is investing $20 million while Prestige Shine Group is contributing $30 million, with proceeds earmarked for launching four to six new superstores in 2026, thereby enhancing competitive positioning.
- Financial Resilience Boost: This financing is expected to strengthen Uxin's balance sheet and enhance overall financial resilience, enabling the company to continue its expansion in China's used car retail market.
- Ongoing Strategic Execution: Uxin will persist in executing its established strategy, leveraging new retail experiences and digital empowerment to drive industry transformation and improve customer satisfaction, ultimately delivering long-term value for shareholders.
See More
Uxin (UXIN) Q4 2025 Earnings Call Transcript
See More
